Asset
BELNACASAN
Vertex Pharmaceuticals Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00205465 | phase2 | completed | 2004-12-01 | — | Vertex Pharmaceuticals Incorporated | Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765 |
| NCT01048255 | phase2 | completed | 2010-01-01 | 2010-11-01 | Vertex Pharmaceuticals Incorporated | Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy |
FDA applications (0)
This company has no applications containing this asset.